PHAT · Phathom Pharmaceuticals Inc
United States · RS rating 13 · As of 2026-11-03
| Price | 5.74 USD |
|---|---|
| 1-day change | -3.0% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 28 / 21 / 18 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 5 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +29.3% |
| Sales growth Q/Q | +16.3% |
| Distance from 52-week high | +68.2% |
| Market cap (USD) | $965.9M |